Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder

Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder Opinion EDITORIAL Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder Maurizio Fava, MD The article by Peciña and colleagues in this issue of JAMA list control. After 2 weeks, participants originally random- Psychiatry reports the results of a study evaluating with a neu- ized to open-label placebo continued for an additional 2 weeks roimaging paradigm the neurochemical mechanisms underly- taking open-label placebo, and participants originally as- ing the formation of placebo signed to the waitlist control were switched to open-label pla- effects in patients with major cebo for an additional 4 weeks, as long as they continued to Related article page 1087 depressive disorder (MDD). meet the eligibility requirements after 2 weeks on the wait- Their study involved perform- list. At the 2-week end point, although there were no statisti- ing a single-blinded 2-week crossover randomized clinical trial cally significant differences between open-label placebo and of 2 identical oral placebos (described as having either active or waitlist primarily owing to the small sample size, the effect size inactive fast-acting antidepressantlike effects), followed by a for the main outcome measure (17-item Hamilton Scale for De- 10-week open-label treatment with an antidepressant. The par- pression score) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder

JAMA Psychiatry , Volume 72 (11) – Nov 1, 2015

Loading next page...
 
/lp/american-medical-association/implications-of-a-biosignature-study-of-the-placebo-response-in-major-g0LaFGCYDr
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2015.1727
pmid
26421499
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Implications of a Biosignature Study of the Placebo Response in Major Depressive Disorder Maurizio Fava, MD The article by Peciña and colleagues in this issue of JAMA list control. After 2 weeks, participants originally random- Psychiatry reports the results of a study evaluating with a neu- ized to open-label placebo continued for an additional 2 weeks roimaging paradigm the neurochemical mechanisms underly- taking open-label placebo, and participants originally as- ing the formation of placebo signed to the waitlist control were switched to open-label pla- effects in patients with major cebo for an additional 4 weeks, as long as they continued to Related article page 1087 depressive disorder (MDD). meet the eligibility requirements after 2 weeks on the wait- Their study involved perform- list. At the 2-week end point, although there were no statisti- ing a single-blinded 2-week crossover randomized clinical trial cally significant differences between open-label placebo and of 2 identical oral placebos (described as having either active or waitlist primarily owing to the small sample size, the effect size inactive fast-acting antidepressantlike effects), followed by a for the main outcome measure (17-item Hamilton Scale for De- 10-week open-label treatment with an antidepressant. The par- pression score)

Journal

JAMA PsychiatryAmerican Medical Association

Published: Nov 1, 2015

References